Li Chuan-Chao, Chi Jun-Lin, Ma Yu, Li Jian-Hong, Xia Chuan-Qin, Li Lin, Chen Zhuo, Chen Xiao-Li
Department of General Surgery, West China Hospital of Sichuan University, Chengdu (610041), China.
Radiat Oncol. 2014 Jun 23;9:144. doi: 10.1186/1748-717X-9-144.
The aim of this study was to investigate the effects of 131I gelatin microspheres (131I-GMS) on human breast cancer cells (MCF-7) in nude mice and the biodistribution of 131I-GMSs following intratumoral injections.
A total of 20 tumor-bearing mice were divided into a treatment group and control group and received intratumoral injections of 2.5 mci 131I-GMSs and nonradioactive GMSs, respectively. Tumor size was measured once per week. Another 16 mice received intratumoral injections of 0.4 mci 131I-GMSs and were subjected to single photon emission computed tomography (SPECT) scans and tissue radioactivity concentration measurements on day 1, 4, 8 and 16 postinjection. The 20 tumor-bearing mice received intratumoral injections of 0.4 mci [131I] sodium iodide solution and were subjected to SPECT scans and intratumoral radioactivity measurements at 1, 6, 24, 48 and 72 h postinjection. The tumors were collected for histological examination.
The average tumor volume in the 131I-GMSs group on post-treatment day 21 decreased to 86.82 ± 63.6%, while it increased to 893.37 ± 158.12% in the control group (P < 0.01 vs. the 131I-GMSs group). 131I-GMSs provided much higher intratumoral retention of radioactivity, resulting in 19.93 ± 5.24% of the injected radioactivity after 16 days, whereas the control group retained only 1.83 ± 0.46% of the injected radioactivity within the tumors at 1 h postinjection.
131I-GMSs suppressed the growth of MCF-7 in nude mice and provided sustained intratumoral radioactivity retention. The results suggest the potential of 131I-GMSs for clinical applications in radiotherapy for breast cancer.
本研究旨在探讨131I明胶微球（131I-GMS）对裸鼠体内人乳腺癌细胞（MCF-7）的影响以及瘤内注射后131I-GMS的生物分布。
将20只荷瘤小鼠分为治疗组和对照组，分别接受瘤内注射2.5毫居里的131I-GMS和非放射性GMS。每周测量一次肿瘤大小。另外16只小鼠接受瘤内注射0.4毫居里的131I-GMS，并在注射后第1、4、8和16天进行单光子发射计算机断层扫描（SPECT）和组织放射性浓度测量。20只荷瘤小鼠接受瘤内注射0.4毫居里的[131I]碘化钠溶液，并在注射后1、6、24、48和72小时进行SPECT扫描和瘤内放射性测量。收集肿瘤进行组织学检查。
治疗后第21天，131I-GMS组的平均肿瘤体积降至86.82±63.6%，而对照组则增至893.37±158.12%（与131I-GMS组相比，P<0.01）。131I-GMS在瘤内的放射性保留率高得多，16天后为注入放射性的19.93±5.24%，而对照组在注射后1小时瘤内仅保留注入放射性的1.83±0.46%。
131I-GMS可抑制裸鼠体内MCF-7的生长，并能在瘤内持续保留放射性。结果表明131I-GMS在乳腺癌放射治疗临床应用方面具有潜力。
